deltatrials
Terminated PHASE4 INTERVENTIONAL 2-arm NCT03276026

A Study to Compare Neostigmine vs Sugammadex in Length of PACU Stay in Patients Undergoing Sleeve Gastrectomy Surgery

A Randomized Prospective Study to Compare the Effectiveness of Neostigmine Versus Sugammadex in Length of PACU Stay in ASA II and III Patients Undergoing Sleeve Gastrectomy Bariatric Surgery

Sponsor: Merck Sharp & Dohme LLC

Conditions Postoperative Nausea and Vomiting Respiratory Conditions Due to Other External Agents
Interventions Neostigmine Sugammadex
Updated 12 times since 2017 Last updated: May 23, 2019 Started: Feb 12, 2018 Primary completion: Nov 8, 2018 Completion: Nov 8, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

PI left the Institution.

Other terminated trials from Merck Sharp & Dohme LLC

More terminations from Merck Sharp & Dohme LLC

Listed as NCT03276026, this PHASE4 trial focuses on Postoperative Nausea and Vomiting and Respiratory Conditions Due to Other External Agents and remains terminated or withdrawn. Sponsored by Merck Sharp & Dohme LLC, it has been updated 12 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Oct 2017 – ~Feb 2018 · 4 months · monthly snapshotNot Yet Recruiting~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshotNot Yet Recruiting~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshotRecruiting~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshotRecruiting~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshotRecruiting~Feb 2019 – ~Jun 2019 · 4 months · monthly snapshotTerminated~Jun 2019 – ~Jan 2021 · 19 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jun 2022 · 6 months · monthly snapshotTerminated~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE4

  3. Jun 2022 — Jul 2024 [monthly]

    Terminated PHASE4

  4. Dec 2021 — Jun 2022 [monthly]

    Terminated PHASE4

  5. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE4

▶ Show 7 earlier versions

  1. Jun 2019 — Jan 2021 [monthly]

    Terminated PHASE4

  2. Feb 2019 — Jun 2019 [monthly]

    Terminated PHASE4

    Status: Recruiting → Terminated

  3. Jun 2018 — Feb 2019 [monthly]

    Recruiting PHASE4

  4. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE4

    Phase: NA → PHASE4

  5. Mar 2018 — Apr 2018 [monthly]

    Recruiting NA

    Status: Not Yet Recruiting → Recruiting

  6. Feb 2018 — Mar 2018 [monthly]

    Not Yet Recruiting NA

  7. Oct 2017 — Feb 2018 [monthly]

    Not Yet Recruiting NA

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
  • Virtua Health, Inc.
Data source: Virtua Health, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations